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This Journal section presents a real, challenging case involving a multidrug-resistant organism. The case authors present the rationale for
their therapeutic strategy and discuss the impact of mechanisms of resistance on clinical outcome. Two expert clinicians then provide a com-
mentary on the case.
We describe a pediatric cystic fibrosis patient who developed a pulmonary exacerbation due to two multidrug-resistant (MDR)
Pseudomonas aeruginosa isolates. In addition to these MDR organisms, the case was further complicated by -lactam allergy.
Despite the MDR phenotype, both isolates were susceptible to an antimicrobial combination.
CASE PRESENTATION
A14-year-old female with a history of cystic fibrosis (CF) and-lactam allergy presented with acute onset of difficulty of
breathing, fever, and productive cough. Initial respiratory culture
grew 2 strains of Pseudomonas aeruginosa. The nonmucoid Pseu-
domonas isolate was resistant to meropenem (MIC, 8 g/ml) and
tobramycin and gentamicin (for both, MIC of8g/ml) but sensi-
tive to ceftazidime (MIC, 8 g/ml), cefepime (MIC, 4 g/ml), pip-
eracillin-tazobactam (TZP; MIC, 2/4 g/ml), ciprofloxacin
(MIC,  0.5 g/ml), and amikacin (MIC, 16 g/ml). The mucoid
Pseudomonas isolate was resistant to tobramycin (MIC,1,024g/
ml) and intermediate to cefepime (MIC, 16 g/ml) but sensitive to
meropenem (MIC, 0.125 g/ml), amikacin (MIC,8 g/ml), TZP
(MIC,2/4g/ml), and ciprofloxacin (MIC,0.5g/ml).
The patient was initially started on intravenous (i.v.) cipro-
floxacin and amikacin treatment. Due to persistent fevers and
increasing oxygen requirement, she underwent desensitization to
TZP on day 6 of hospitalization because of history of cefepime
allergy (rash). Because it was not clear whether this was an imme-
diate-type sensitivity reaction and because of her critical respi-
ratory status, desensitization to TZP was executed. Piperacil-
lin-tazobactam at 2,400 mg was infused (over 1 h) every 6 h.
Ciprofloxacin was continued. Because of lack of clinical improve-
ment, extended infusion (over 3 h) of TZP was initiated on day 14
of hospitalization. However, minimal clinical improvement was
noted over the next several days, and repeat respiratory culture
obtained on day 15 of hospitalization revealed the development of
multidrug resistance (MDR) in themucoid strain, which was now
resistant to cefepime (MIC, 32 g/ml) and intermediate to TZP
(MIC, 32/4 g/ml) and ciprofloxacin (MIC, 2 g/ml) (see Table
S1 in the supplemental material).
CHALLENGE QUESTION
What would be the best treatment option for this patient at this
time?
A. Ceftazidime-avibactam (C/A)
B. Ceftolozane-tazobactam (C/T)
C. Continuous piperacillin-tazobactam infusion
D. Combination treatment with ceftazidime and ciprofloxacin
TREATMENT AND OUTCOME
Additional susceptibility testing of the Pseudomonas isolates re-
vealed sensitivity to C/T in both mucoid and nonmucoid Pseu-
domonas strains (mucoid strain MIC, 0.5 g/ml; nonmucoid
strain MIC, 1 g/ml). On day 20 of hospitalization, the patient
underwent C/T desensitization (see Table S2 in the supplemental
material) to a cumulative dose of 1.5 g and then C/T was given at
1.5 g every 8 h (q8h) (equivalent to 93 mg/kg of body weight/day
of ceftolozane component) based on approved dosing for adults
(1). Ciprofloxacin i.v. (30 mg/kg/day) was continued for double
coverage of MDR Pseudomonas. A validated high-performance
liquid chromatography (HPLC)methodwas utilized to determine
the plasma concentrations of ceftolozane and tazobactam at the
Center for Anti-Infective Research and Development, Hartford
Hospital, Hartford, CT. Blood samples (n  4) were collected
after administration of the fourth dose of C/T 1.5 g q8h given as a
1-h intravenous infusion. Pharmacokinetic (PK) parameters of
C/T were modeled from their total concentrations in the plasma
using one-compartment first-order input and elimination, by
nonlinear least-squares techniques (Phoenix version 6.3; Phar-
sight Corp., Mountain View, CA). Compartment model selection
was based on visual inspection of the pharmacokinetic profile and
use of the correlation between the observed and calculated con-
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centrations. Since the percentage of the dosing interval in which
free drug concentrations remain above the MIC (%fTMIC) is
the pharmacodynamic parameter that correlates with the antimi-
crobial efficacy of -lactams (2), the pharmacokinetic parameters
derived from the patient’s C/T concentration-time profile were
used to simulate a variety of C/T dosing regimens (1.5 g q8h given
as 1-h infusion, 1.5 g q8h as 3-h infusion, 1.5 g q6h as 1-h infusion,
1.5 g q6h as 3-h infusion, 3 g q8h as 1-h infusion, and 3 g q8h as 3-h
infusion) to highlight the impact of altering the dose and/or du-
ration of infusion on drug exposures (i.e., %fTMIC). Free cef-
tolozane concentrations were calculated based on mean percent-
age of plasma protein binding of 19% (range, 16 to 21%) (1). The
%fTMIC of ceftolozane was calculated usingMIC values of 0.5,
1, 2, 4, and 8g/ml. These ceftolozaneMIC values were selected to
encompass the MICs observed in the current case as well as the
MIC50 (2 g/ml) and MIC90 (8 g/ml) previously reported for P.
aeruginosa derived from a CF population (3).
Modeled pharmacokinetic estimates of ceftolozane and tazo-
bactam based on total plasma concentrations of the two com-
pounds are shown inTable 1. Calculations of%fTMICvalues of
ceftolozane for each of the simulated doses against the testedMIC
range are shown in Table 2. All regimens exceeded the target
fTMIC of 40% (4) against the tested MICs where the lowest
value was 56.3% and seen with the first regimen of 1.5 g q8h as 1-h
infusion against MIC of 8 g/ml.
Although C/A was a possible option, C/T was thought to be
better than ceftazidime-avibactambecause C/T has been shown in
vitro to have enhanced potency againstMDRP. aeruginosa isolates
that have chromosomal AmpC enzymes, upregulation of efflux
pumps, or loss of outer membrane porin, including carbapenem-
resistant strains, for which C/A is less active. In addition, C/T was
well tolerated when given in high doses to CF patients who may
present with rapid drug clearance (5, 6). A recent study by Kuti
and colleagues showed that C/Twas associatedwith potent in vitro
activity against P. aeruginosa isolates collected from children with
CF, as bacterial susceptibility to the compound was 86% com-
pared with 46%, 58%, and 50% for meropenem, ceftazidime, and
piperacillin-tazobactam, respectively (3). Similarly, another study
by Zamorano et al. showed superior in vitro potency of C/T to
comparator antibiotics against P. aeruginosa isolates, including
MDR isolates, from CF patients chronically infected with the or-
ganism (7). Although the P. aeruginosa isolate was susceptible to
ceftazidime, it was not used in the setting of cefepime resistance.
Since our patient was already receiving themaximumdose of TZP
with extended infusion, continuous TZP infusion was not felt to
be beneficial.
When the modeled pharmacokinetics of ceftolozane in our
patient were compared with the parameters observed in healthy
adult volunteers following a dose of 1.5 g q8h over 1 h (1), a higher
peak plasma concentration (94.1 versus 74.4 g/ml), a shorter
half-life (1.1 versus 3.1 h), and a smaller volume of distribution
(7.9 versus 13.5 liters) were seen in our pediatric patient. The short
half-life indicates a faster clearance profile of ceftolozane, which
can be attributed to her pediatric status as well as her underlying
CF, a disease state which is generally associated with faster body
clearance of drugs (6).
The reported target fTMIC of ceftolozane against P. aerugi-
nosa for 1-log killing is 40% (4). In this study, we showed that C/T
administered at a dose of 1.5 g q8h over 1 h in this 32-kgCFpatient
was associated with pharmacodynamic target achievement of
40% fTMIC against the two P. aeruginosa isolates with MICs
of 0.5 and 1 g/ml. Moreover, we demonstrated that the utili-
zation of a higher dose, more frequent administration, and/or
prolonged infusion of C/T in this pediatric patient offers the
opportunity for pharmacodynamic optimization with organ-
isms displaying a MIC value up to 8 g/ml.
There was rapid improvement in her respiratory status, with
successful wean of supplemental oxygen from 6 liters to room air
over the following 5 days after C/T was initiated. On day 6 of C/T
therapy, she was noted to have mild transaminitis (alanine ami-
notransferase [ALT] level increased from 51 to 106 units/liter over
the last week). Additionally, she was also concomitantly receiving
i.v. daptomycin treatment for Staphylococcus aureus-associated
catheter-related bloodstream infection and completed a 14-day
course 1 day earlier. Thus, the etiology of this mild transaminitis
was not clear. Nevertheless, a 50% dose reduction of C/T was
initiated (new dose, 750 mg q8h; 46.5-mg/kg/day ceftolozane
component) with subsequent improvement in transaminitis noted 5
days later (ALT level, 77 units/liter). No other adverse events were
attributed to C/T in this-lactam-allergic pediatric patient. Upon
completion of a 14-day i.v. antibiotic course of C/T and cipro-
floxacin, she was discharged in stable condition (see Fig. S1 in the
supplemental material). At the 2-week-postdischarge follow-up,
she had returned to baseline respiratory status, remained afebrile,
was tolerating her home g-tube feeds, and remained well at her
next follow-up 3 months later.
In conclusion, C/T provided a potent in vitro option despite
theMDRphenotypic profile displayed by theP. aeruginosa isolates
TABLE 1Modeled pharmacokinetic parameters of ceftolozane and tazobactam at steady state based on total plasma concentrations
(one-compartment model)a
Drug Cmax (g/ml) Cmin (g/ml) AUC0–8 (g · h/ml) V (liters) kel (h
1) t1/2 (h) CL (liters/h)
Ceftolozane 94.1 1.2 201.1 7.9 0.6 1.1 5.0
Tazobactam 12.1 0.04 21.4 28.1 0.8 0.8 23.3
a V, volume of distribution; kel, elimination rate constant; t1/2, half-life; Cmax, peak plasma concentration; Cmin, trough plasma concentration; AUC0–8, area under drug
concentration-time curve for the dosing interval; CL, clearance.
TABLE 2 Calculations of %fTMIC values of simulated ceftolozane-
tazobactam dosing regimens
Dose (duration of
intravenous infusion)
%f TMIC against MIC (g/ml):
0.5 1 2 4 8
1.5 g q8h (1 h) 100 97.50 83.75 70 56.3
1.5 g q8h (3 h) 100 100 98.75 84.6 69.6
1.5 g q6h (1 h) 100 100 100 94.6 76.3
1.5 g q6h (3 h) 100 100 100 99.6 95.4
3 g q8h (1 h) 100 100 100 92.5 78.8
3 g q8h (3 h) 100 100 100 100 93.8
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infecting our pediatric patient. As such, this new compound was a
viable option for our patient and thus may be considered a potent
alternative agent to treat patients with CF infected with P. aerugi-
nosa. Despite the -lactam allergy of our patient and a milligram-
per-kilogram dose that was 2 to 3 times that observed in adults,
C/T was well tolerated.Moreover, this case also provides pharma-
cokinetic data in support of the currently utilized 1.5-g q8h dose
administered over 1 h in this pediatric patient and further reveals
that manipulations of the dose, dosing interval, and/or infusion
duration may provide opportunities to optimize the exposures of
C/T up to a MIC of 8 g/ml. Since the pharmacokinetics of drugs
may be altered in patients with CF, additional studies assessing the
pharmacokinetics of C/T in this patient population arewarranted.
COMMENTARY
Respiratory infections caused by Pseudomonas aeruginosa are
common in patients with CF and are associated with decreased
lung function and survival (8). In particular, patients with CF are
prone to becoming colonized and infected with mucoid pheno-
types of P. aeruginosa. This case describes treatment-emergent
resistance in mucoid P. aeruginosa in an adolescent with CF.
This case highlights the remarkable ability of P. aeruginosa to
develop resistance during antimicrobial therapy, particularly in
the setting of pneumonia. In a randomized clinical trial that com-
pared doripenem to imipenem for ventilator-associated pneumo-
nia (VAP), carbapenem resistance developed while on therapy in
approximately one-third of cases caused by P. aeruginosa (9). This
high rate of developing resistance on therapy is due to themultiple
mechanisms of resistance that P. aeruginosa can upregulate in the
presence of -lactam agents, such as increased production of ef-
flux pumps and AmpC -lactamases (10). Combination therapy
with a-lactam and a fluoroquinolone, as used in this patient, has
demonstrated the ability to suppress the emergence of resistance
to either agent in a murine model of P. aeruginosa pneumonia
(11). However, the ability of combination therapy to prevent the
emergence of resistance has not been properly evaluated in clinical
studies and prevention was not successful in this case. Further-
more, various hypermutable P. aeruginosa clones with different
resistance phenotypes may coexist, andMDR clones may become
dominant under antibiotic pressure (12).
An additional strategy that was used in this patient was extend-
ed-infusion TZP. The rationale for this extended infusion is to
maximize the time that the free concentration of TZP is greater
than theMIC, which is correlated with optimal bactericidal killing
in preclinical models. Observational studies have demonstrated
improved clinical outcomes in critically ill patients with P. aerugi-
nosa infectionwho receive a prolonged infusion of TZP compared
with a 30-min infusion (13). Unfortunately, by the time that ex-
tended-infusion TZPwas initiated in this patient, theMIC against
the mucoid strain of P. aeruginosa had increased to 32/4 g/ml
(intermediate). At this MIC, even an extended-infusion regimen
of TZP may not yield adequate exposures that are required for
maximal bactericidal activity.
C/T therapy was then initiated and resulted in a good clinical
response in this patient. C/T is a newly available antimicrobial
agent with enhanced in vitro activity against P. aeruginosa com-
pared to other cephalosporins (14). Approximately 70% of P.
aeruginosa strains that are not susceptible to ceftazidime, mero-
penem, andTZP are susceptible toC/T based onCLSI breakpoints
(14). The enhanced antipseudomonal activity of this combination
is due to ceftolozane, as tazobactam does not inhibit AmpC-lac-
tamases produced by this organism. To date, the efficacy of C/T
has been evaluated only in clinical trials of complicated urinary
tract and intra-abdominal infections (14). Furthermore, these tri-
als enrolled very few patients with MDR P. aeruginosa infections.
A randomized clinical trial is under way (ClinicalTrials.gov regis-
tration no. NCT02070757) to evaluate the safety and efficacy of
C/T for VAP.
An additional important component of this case was the as-
sessment of C/T bloodstream concentrations to establish a phar-
macokinetic (PK)model for this agent in adolescent patients with
CF. The PK parameters identified in this patient were different
from those observed in healthy adult volunteers, highlighting the
importance of studies that assess PK parameters in critically ill pa-
tients, including pediatric patients. Using PK modeling, the authors
found that the U.S. FDA-approved adult dosage of 1.5 g q8h in this
32-kg adolescent would reliably achieve the optimal pharmacody-
namic target for P. aeruginosa strains with C/T MICs of 0.5 or 1
g/ml. This dosage, in milligrams per kilogram, is similar to the 3-g
q8h dosage that is being evaluated in the clinical trial of C/T for VAP
in adults. The authors’ PK modeling also suggests that prolonged
infusions of C/T or q6h dosing may be necessary to reliably achieve
target exposures when the C/TMIC is 4 to 8g/ml.
This illustrative case highlights the remarkable capacity for P.
aeruginosa to develop resistance on therapy and the potential role
of C/T for MDR P. aeruginosa pneumonia. Additional studies are
needed to identify the optimal dosing of C/T for this indication,
particularly in pediatric patients with CF who are highly vulnera-
ble to these infections.
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